Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma

[1]  A. Hauschild,et al.  Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells , 2017, JAMA dermatology.

[2]  A. Hauschild,et al.  Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma , 2017, Oncoimmunology.

[3]  M. Tronnier,et al.  PD‐1 and PD‐L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma , 2017, Journal of cutaneous pathology.

[4]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[5]  G. Linette,et al.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[6]  A. Italiano,et al.  Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype , 2016, Modern Pathology.

[7]  Jaime Rodriguez-Canales,et al.  Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients , 2016, Clinical Cancer Research.

[8]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[9]  P. Coto-Segura,et al.  Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta‐analysis , 2015, The British journal of dermatology.

[10]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[11]  A. Burlingame,et al.  NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling. , 2015, Advances in biological regulation.

[12]  Y. Narisawa,et al.  Histogenesis of pure and combined Merkel cell carcinomas: An immunohistochemical study of 14 cases , 2015, The Journal of dermatology.

[13]  D. Rimm,et al.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites , 2015, Clinical Cancer Research.

[14]  C. Larsson,et al.  TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma , 2014, Oncotarget.

[15]  T. Olencki,et al.  Merkel cell carcinoma, version 1.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  Luciane T. Kagohara,et al.  PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival , 2013, Cancer Immunology Research.

[17]  V. Sondak,et al.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. , 2010, Journal of the American Academy of Dermatology.

[18]  Z. Korade,et al.  p75 Neurotrophin Receptor-mediated Apoptosis in Sympathetic Neurons Involves a Biphasic Activation of JNK and Up-regulation of Tumor Necrosis Factor-α-converting Enzyme/ADAM17* , 2010, The Journal of Biological Chemistry.

[19]  J. Riley.  PD‐1 signaling in primary T cells , 2009, Immunological reviews.

[20]  Y. Sakamoto,et al.  Combined evaluation of NGF and p75NGFR expression is a biomarker for predicting prognosis in human invasive ductal breast carcinoma. , 2001, Oncology reports.

[21]  M. Freidin.  Antibody to the extracellular domain of the low affinity NGF receptor stimulates p75NGFR‐mediated apoptosis in cultured sympathetic neurons , 2001, Journal of neuroscience research.

[22]  F. Speleman,et al.  Frequent allelic loss at 10q23 but low incidence of PTEN mutations in merkel cell carcinoma , 2001, International journal of cancer.

[23]  R. W. Miller,et al.  Merkel cell carcinoma and melanoma: etiological similarities and differences. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  D. G. Coit.  Merkel cell carcinoma. , 1998, Annals of surgical oncology.

[25]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[26]  S. Bonini,et al.  Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. , 1997, The Journal of allergy and clinical immunology.

[27]  D. Kaplan,et al.  The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. , 1991, Science.

[28]  R. Levi‐montalcini,et al.  The nerve growth factor 35 years later. , 1987, Science.

[29]  Guangpu Li,et al.  Biogenesis and function of the NGF/TrkA signaling endosome. , 2015, International review of cell and molecular biology.

[30]  Brian J. Wiltgen,et al.  NF-kappa B functions in synaptic signaling and behavior. , 2003, Nature neuroscience.

[31]  H. Friess,et al.  Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.